Abstract 380: Short-term Treatment with Lercanidipine May Modulate Insuling Signalling and Oxidative Stress in Hypertensive Patients

    loading  Checking for direct PDF access through Ovid

Abstract

We investigated the effects of antihypertensive treatment with two drug combinations on insulin signalling and oxidative stress.

Twenty essential hypertensive patients were included in the study and treated for 4 weeks with lercanidipine orally. Then they were treated for 6 months with lercanidipine+enalapril (n=10) or lercanidipine+hydrochlorothiazide (n=10). Investigations were performed in basal condition, after 4 weeks of monotherapy with lercanidipine, and at the end of the combination treatment. Insulin signalling was evaluated in mononuclear cells by Wester-Blot. Circulating levels of C-reactive protein (CRP), proinflammatory cytokines interleukin-6 and interleukin-18 (IL-18), macrophage chemotactic factor-1 (MCP-1), soluble vascular cell adhesion molecule 1 and soluble inter-cellular adhesion molecule 1, malonyldialdehyde and lipid peroxidation were measured in plasma.

Results are summarized in the Table (*P<0.05, **p<0.01 vs. Basal; #p<0.05 vs. lercanipine alone). An increased expression of insulin receptor, GLUT-4 and an increased activation of p70S6K1 were observed during treatment with lercanidipine+enalapril but not with lercanidipine+hydrochlorothiazide. A reduction in circulating levels of IL 18, CRP and MCP-1 was observed after treatment with lercanidipine alone, which persisted or further improved after treatment with lercanidipine+enalapril but not with lercanidipine+hydrochlorothiazide.

Therefore the combination treatment lercanidipine+enalapril seems more effective than lercanidipine+hydrochlorothiazide in activating insulin signalling, possibly due to a more marked antioxidant/antiinflammatory effect.

Related Topics

    loading  Loading Related Articles